Epeius Biotechnologies' lead product, Rexin-G, has been granted Fast Track designation by the FDA for use as a second-line treatment for advanced or metastatic pancreatic cancer. The drug is currently in Phase II trials. Release
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments